Other Viruses Citation List: August 2 - August 15, 2013
Hepatitis C Virus
1. NS5A Inhibitor, Daclatasvir , for the Treatment of Chronic Hepatitis C Virus Infection. Herbst, D.A. and K.R. Reddy. Expert Opinion on Investigational Drugs, 2013. [Epub ahead of print]; PMID[23931586].
[PubMed] OV_0802-081513.
2. Novel Imino Sugar Alpha-Glucosidase Inhibitors as Antiviral Compounds. Howe, J.D., N. Smith, M.J. Lee, N. Ardes-Guisot, B. Vauzeilles, J. Desire, A. Baron, Y. Bleriot, M. Sollogoub, D.S. Alonzi, and T.D. Butters. Bioorganic & Medicinal Chemistry, 2013. 21(16): p. 4831-4838; PMID[23582447].
[PubMed] OV_0802-081513.
3. A Conformational Mimetic Approach for the Synthesis of Carbocyclic Nucleosides as anti-HCV Leads. Kasula, M., T. Balaraju, M. Toyama, A. Thiyagarajan, C. Bal, M. Baba, and A. Sharon. ChemMedChem, 2013. [Epub ahead of print]; PMID[23943612].
[PubMed] OV_0802-081513.
4. Development of a Practical, Asymmetric Synthesis of the Hepatitis C Virus Protease Inhibitor MK-5172. Kuethe, J., Y.L. Zhong, N. Yasuda, G. Beutner, K. Linn, M. Kim, B. Marcune, S.D. Dreher, G. Humphrey, and T. Pei. Organic Letters, 2013. [Epub ahead of print]; PMID[23919347].
[PubMed] OV_0802-081513.
5. Cyclophilin Inhibitors as Antiviral Agents. Peel, M. and A. Scribner. Bioorganic & Medicinal Chemistry Letters, 2013. 23(16): p. 4485-4492; PMID[23849880].
[PubMed] OV_0802-081513.
6. Highly Efficient Infectious Cell Culture of Three HCV Genotype 2b Strains and Sensitivity to Lead Protease, NS5A, and Polymerase Inhibitors. Ramirez, S., Y.P. Li, S.B. Jensen, J. Pedersen, J.M. Gottwein, and J. Bukh. Hepatology, 2013. [Epub ahead of print]; PMID[23913364].
[PubMed] OV_0802-081513.
7. Tetrazole and Triazole as Bioisosteres of Carboxylic Acid: Discovery of Diketo Tetrazoles and Diketo Triazoles as anti-HCV Agents. Song, W.H., M.M. Liu, D.W. Zhong, Y.L. Zhu, M. Bosscher, L. Zhou, D.Y. Ye, and Z.H. Yuan. Bioorganic & Medicinal Chemistry Letters, 2013. 23(16): p. 4528-4531; PMID[23856047].
[PubMed] OV_0802-081513.
8. In Vitro Characterization of GSK5852, a Novel HCV Polymerase Inhibitor. Voitenleitner, C., R. Crosby, J. Walker, K. Remlinger, J. Vamathevan, A. Wang, S. You, J. Johnson, 3rd, E. Woldu, S. Van Horn, J. Horton, K. Creech, J.B. Shotwell, Z. Hong, and R. Hamatake. Antimicrobial Agents and Chemotherapy, 2013. [Epub ahead of print]; PMID[23939896].
[PubMed] OV_0802-081513.
9. Preclinical Characterization of the Novel Hepatitis C Virus NS3 Protease Inhibitor GS-9451. Yang, H., M. Robinson, A.C. Corsa, B. Peng, G. Cheng, Y. Tian, Y. Wang, R. Pakdaman, M. Shen, X. Qi, H. Mo, C. Tay, S. Krawczyk, X.C. Sheng, C.U. Kim, C. Yang, and W.E.t. Delaney. Antimicrobial Agents and Chemotherapy, 2013. [Epub ahead of print]; PMID[23939899].
[PubMed] OV_0802-081513.
Human Cytomegalovirus
10. Ribonucleotide Reductase Inhibitors Hydroxyurea, Didox, and Trimidox Inhibit Human Cytomegalovirus Replication in Vitro and Synergize with Ganciclovir. Bhave, S., H. Elford, and M.A. McVoy. Antiviral Research, 2013. [Epub ahead of print]; PMID[23933116].
[PubMed] OV_0802-081513.
11. Broad-spectrum Antiviral Activity of Chebulagic Acid and Punicalagin against Viruses That Use Glycosaminoglycans for Entry. Lin, L.T., T.Y. Chen, S.C. Lin, C.Y. Chung, T.C. Lin, G.H. Wang, R. Anderson, C.C. Lin, and C.D. Richardson. BMC Microbiology, 2013. 13: p. 187; PMID[23924316].
[PubMed] OV_0802-081513.
Citations from the ISI Web of Knowledge Listings for O.V.
12. Allosteric N-Acetamide-indole-6-carboxylic acid Thumb Pocket 1 Inhibitors of Hepatitis C Virus NS5B Polymerase - Acylsulfonamides and Acylsulfamides as Carboxylic acid Replacements. Beaulieu, P.L., R. Coulombe, J. Gillard, C. Brochu, J.M. Duan, M. Garneau, E. Jolicoeur, P. Kuhn, M.A. Poupart, J. Rancourt, T.A. Stammers, B. Thavonekham, and G. Kukolj. Canadian Journal of Chemistry, 2013. 91(1): p. 66-81; ISI[000321432300009].
[WOS] OV_0802-081513.
13. 3-Biphenylimidazo[1,2-a]pyridines or [1,2-b]pyridazines and Analogues, Novel Flaviviridae Inhibitors. Enguehard-Gueiffier, C., S. Musiu, N. Henry, J.B. Veron, S. Mavel, J. Neyts, P. Leyssen, J. Paeshuyse, and A. Gueiffier. European Journal of Medicinal Chemistry, 2013. 64: p. 448-463; ISI[000321230300046].
[WOS] OV_0802-081513.
14. New Direct-active Antiviral Agents for Hepatitis C Virus Infection in Previous Treatment Failure. Hoepelman, A.I.M. International Journal of Antimicrobial Agents, 2013. 42: p. S3-S4; ISI[000321447400009].
[WOS] OV_0802-081513.
15. Identification of a Series of Compounds with Potent Antiviral Activity for the Treatment of Enterovirus Infections. MacLeod, A.M., D.R. Mitchell, N.J. Palmer, H.V. de Poel, K. Conrath, M. Andrews, P. Leyssen, and J. Neyts. ACS Medicinal Chemistry Letters, 2013. 4(7): p. 20-24; ISI[000321883800006].
[WOS] OV_0802-081513.
16. Very Low-density Lipoprotein/Lipo-viro Particles Reverse Lipoprotein Lipase-mediated Inhibition of Hepatitis C Virus Infection Via Apolipoprotein C-III. Sun, H.Y., C.C. Lin, J.C. Lee, S.W. Wang, P.N. Cheng, I.C. Wu, T.T. Chang, M.D. Lai, D.B. Shieh, and K.C. Young. Gut, 2013. 62(8): p. 1193-1203; ISI[000321337600016].
[WOS] OV_0802-081513.
17. Elucidation of the Pharmacophore of Echinocystic acid, a New Lead for Blocking HCV Entry. Wang, H., Q. Wang, S.L. Xiaoa, F. Yu, M. Ye, Y.X. Zheng, C.K. Zhao, D.A. Sun, L.H. Zhang, and D.M. Zhou. European Journal of Medicinal Chemistry, 2013. 64: p. 160-168; ISI[000321230300017].
[WOS] OV_0802-081513.